Fecal microbiota transplantation as novel therapy in gastroenterology: A systematic review

Table 6 Studies on fecal microbiota transplantation in inflammatory bowel disease, treatment and outcome data

Author	Publication year	Patients enrolled (n)	Diagnose, disease activity	Age (mean ± SD or median,range/ IQR)	Male sex (n)	FU (mo)	Medication use during study (n)	Timepoint primary endpoint (mo)	Clinical improvement	Clinical remission	Cessation of medication during FU (n/total number of patients on the drug)
Angelberger	2013	5	Refractory UC	27 (22-51)	3	7	5-asa (3), Immunosuppressive therapy stopped prior to FMT	3	20%		0
Borody	2012	62	Active UC	M: 42.3 ± 11.5 F: 48.45 ± 16.49	40	1-1981		NM	92%	68%
Greenberg	2013	16	Refractory CD (2)/UC (14)2	39 (20-75)	9	4.5-30	Steroids (10), antitnf (4), 6MP (1)	After FMT	63%		Steroids: stopped (4/10), decreased dose (3/10). anti-TNF stopped (1/4)
Kump	2013	9	Refractory UC	NM	NM	3		3	56%
Kump	2013	6	Refractory UC	36 (17-52)	3	12		3	33%	0%
Kunde	2013	103	Active UC4	(7-20)	6	3	5-asa (7), 6MP (4), steroids (3)	0.25	70%	30%	0
Vermeire	2012	4	Refractory CD	37.5 (29-50)	1	2		2	0%	0%

¹Endoscopic follow-up (n = 21);

²Concomitant CDI was present in 4 UC patients;

³Ref Kunde: 1 subject did not tollerate treatment, this subject was considered to be a treatment failure. Endpoint data of the study was adjusted in this table;

⁴Active disease diagnosed by colonoscopy < 6 mo before the enrollment. UC: Ulcerative colitis; FMT: Fecal microbiota transplantation; CD: Crohn’s disease; FU: Follow-up; NM: Not mentioned.